Erratum: Effects of serum homocysteine and adiponectin levels on platelet aggregation in untreated patients with essential hypertension (Journal of Thrombosis and Thrombolysis DOI: 10.1007/s11239-008-0292-0);Effects of serum homocysteine and adiponectin levels on platelet aggregation in untreated patients with essential hypertension

Journal of Thrombosis and Thrombolysis

Volumn 28, Issue 4, 2009, Pages 418-424

  Ekmekçi, Hakan ^a,b   Ekmekçi, Özlem Balci ^a   Erdine, Serap ^c   Sönmez, Hüseyin ^c   Ataev, Yusup ^c   Öztürk, Zeynep ^c   Bütün, Ílknur Işler ^c   Gürel, Çiǧdem ^c   Kucur, Mine ^c   Turfaner, Nurver ^c   Ulutin, Turgut ^c   Purisa, Sevim ^c   Vural, Vural Ali ^c  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Seyit Omer Mahallesi   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Adiponectin; Essential hypertension; Homocysteine; Platelet aggregation; Volunteers

Indexed keywords

ADENOSINE DIPHOSPHATE; ADIPONECTIN; C REACTIVE PROTEIN; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; NITRIC OXIDE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CHEMOLUMINESCENCE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE AGGREGATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 70350522004     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-009-0390-7     Document Type: Erratum

References (41)

1. Ekmekci OB, Donma O, Tunckale A (2003) Angiotensin-converting enzyme and metals in untreated essential hypertension. Biol Trace Elem Res 95(3):203-210
2. Binder A (2007) A review of the genetics of essential hypertension. Curr Opin Cardiol 22(3):176-184
3. Messerli FH, Williams B, Ritz E (2007) Essential hypertension. Lancet 370(9587):591-603
4. Gebara OC, Jimenez AH, McKenna C, Mittleman MA, Xu P, Lipinska I et al (1996) Stress-induced hemodynamic and hemostatic changes in patients with systemic hypertension: Effect of verapamil. Clin Cardiol 19(3):205-211
5. Somova L, Mufunda J (1993) Platelet activity and salt sensitivity in the pathogenesis of systemic (essential) hypertension in black Africans. Clin Exp Hypertens 15(5):781-796
6. Varughese GI, Lip GY (2005) Is hypertension a prothrombotic state? Curr Hypertens Rep 7(3):168-173
7. Selhub J (1999) Homocysteine metabolism. Annu Rev Med 19:217-246
8. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C (1997) High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 96:1745-1749
9. Mendis S, Athauda SB, Naser M, Takahashi K (1999) Association between hyperhomocysteinaemia and hypertension in Sri Lankans. J Int Med Res 27:38-44
10. Rodrigo R, Passalacqua W, Araya J, Orellana M, Rivera G (2003) Homocysteine and essential hypertension. J Clin Pharmacol 43(12):1299-1306
11. Den Heijer M, Koster T, Blom HJ et al (1996) Hyperhomocysteinaemia as a risk factor for deep vein thrombosis. N Engl J Med. 334:759-762
12. Den Heijer M, Lewington S, Clarke R (2005) HCY, MTHFR, and risk of venous thrombosis: A meta-analysis of published epidemiological studies. J Thromb Haemost 3:292-299
13. Ekmekci H, Ekmekci OB (2006) The role of adiponectin in atherosclerosis and thrombosis. Clin Appl Thromb Hemost 12(2):163-168
14. Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, Fong CH, Ong LH, Tam S, Tan KC, Janus ED, Lam TH, Lam KS (2007) Hypoadiponectinemia as a predictor for the development of hypertension: A 5-year prospective study. Hypertension 49(6):1455-1461
15. Furuhashi M, Ura N, Higashiura K, Miyazaki Y, Murakami H, Hyakukoku M, Shimamoto K (2005) Low adiponectin level in young normotensive men with a family history of essential hypertension. Hypertens Res 28(2):141-146
16. Kato H, Kashiwagi H, Shiraga M, Tadokoro S, Kamae T, Ujiie H, Honda S, Miyata S, Ijiri Y, Yamamoto J, Maeda N, Funahashi T, Kurata Y, Shimomura I, Tomiyama Y, Kanakura Y (2006) Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 26(1):224-230
17. Hale LP, Craver KT, Berrier AM, Case LD, Owen J (1998) Combination of fosinopril and rovastatin decreases platelet response to thrombin receptor agonist in monkeys. Arterioscler Thromb Vasc Biol 18:1643-1646
18. Taylor RR, Strophair J, Sturm M, Vandongen R, Beilin LJ (1988) Time dependence of whole blood aggregation in response to platelet activating factor (PAF). Thromb Haemost 59:162-163
19. Gleerup G, Winther K (1995) The effect of ageing on platelet function and fibrinolytic activity. Angiology 46(8):715-718
20. Rubies-Prat J, Ordóñez-Llanos J, Martin S, Blanco-Vaca F, Molina L, Goday A, Pedro-Botet J (2001) Low-density lipoprotein particle size triglyceride-rich lipoproteins and glucose tolerance in non-diabetic men with essential hypertension. Clin Exp Hypertens 23(6):489-500
21. Flesch M, Sachinidis A, Ko YD, Kraft K, Vetter H (1994) Plasma lipids and lipoproteins and essential hypertension. Clin Investig 72(12):944-950
22. Kashyap MK, Yadav V, Sherawat BS, Jain S, Kumari S, Khullar M, Sharma PC, Nath R (2005) Different antioxidants status, total antioxidant power and free radicals in essential hypertension. Mol Cell Biochem 277(1-2):89-99
23. Lentz SR (2005) Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 3(8):1646-1654
24. Weiss N, Keller C, Hoffmann U, Loscalzo J (2002) Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vasc Med 7(3):227-239
25. Starkebaum G, Harlan JM (1986) Endothelial cell injury due to copper-catalysed hydrogen peroxide generation from HCY. J Clin Invest 77:1370-1376
26. Jia L, Furchgott RF (1993) Inhibition of sulfhydryl compounds of vascular relaxation induced by nitric oxide and endothelium-derived relaxing factor. J Pharmacol Exp Ther 267:371-378
27. Loscalzo J (1996) The oxidant stress of hyperhomocysteinaemia. J Clin Invest 98:5-7
28. Upchurch GR, Welch GN, Fabian AJ, Pigazzi A, Keaney JF, Loscalzo J (1997) Stimulation of endothelial nitric oxide production by homocyst(e)ine. Atherosclerosis 132:177-185
29. Fu Y-F, Xiong Y, Guo Z (2005) A reduction of endogenous asymmetric dimethylarginine contributes to the effect of captopril on endothelial dysfunction induced by homocysteine in rats. Eur J Pharmacol 508:167-175
30. Böger RH, Lentz SR, Bode-Böger SM, Knapp HR, Haynes WG (2001) Elevation of asymmetric dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inemia in humans. Clin Sci 100:161-167
31. Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O, Szuba A, Malinow MR, Wascher TC, Pachinger O, Cooke JP (2003) Endothelial dysfunction induced by hyperhomocyst(e)inemia: Role of asymmetric dimethylarginine. Circulation 108:933-938
32. Mohan IV, Jagroop IA, Mikhailidis DP, Stansby GP (2008) Homocysteine activates platelets in vitro. Clin Appl Thromb Hemost 14(1):8-18
33. Ekmekci H, Isler I, Sonmez H, Gurel C, Ciftci O, Ulutin T, Kokoglu E, Domanic N, Dirican A (2006) Comparison of platelet fibronectin, ADP-induced platelet aggregation and serum total nitric oxide (NOx) levels in angiographically determined coronary artery disease. Thromb Res 117(3):249-254
34. Alonso D, Radomski MW (2003) Nitric oxide, platelet function, myocardial infarction and reperfusion therapies. Heart Fail Rev 8(1):47-54
35. Lauer T, Preik M, Rassaf T, Strauer BE, Deussen A, Feelisch M et al (2001) Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proc Natl Acad Sci USA 98(22):12814-12819
36. Imatoh T, Miyazaki M, Une H (2007) Does elevated high-sensitivity serum C-reactive protein associate with hypertension in non-obese Japanese males? Clin Exp Hypertens 29(6):395-401
37. Lakoski SG, Herrington DM, Siscovick DM, Hulley SB (2006) C-reactive protein concentration and incident hypertension in young adults: The CARDIA study. Arch Intern Med 166:345-349
38. Tsunoda K, Arita M, Yukawa M, Ueyama M, Furuta M, Nakagawa T, Nanjo K, Sanke T (2005) Retinopathy and hypertension affect serum high-sensitivity C-reactive protein levels in type 2 diabetic patients. J Diabetes Complications 19:123-127
39. Cottone S, Mule G, Nardi E, Vadala A, Guarneri M, Briolotta C, Arsena R, Palermo A, Riccobene R, Cerasola G (2006) Relation of C-reactive protein to oxidative stress and to endothelial activation in essential hypertension. Am J Hypertens 19:313-318
40. Friso S, Jacques PF, Wilson PW, Rosenberg IH, Selhub J (2001) Low circulating vitamin B(6) is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. Circulation 103:2788-2791
41. Rohde LE, Hennekens CH, Ridker PM (1999) Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol 84:1018-1022